Mitomycin C is a naturally derived antineoplastic antibiotic and potent DNA cross-linking agent used in pharmaceutical oncology applications. It belongs to the mitomycin class of compounds and is known for its ability to interfere with DNA synthesis after enzymatic activation within cells.
Mitomycin C is an established pharmaceutical active ingredient used in specific oncology formulations and is also relevant to pharmaceutical research, analytical development and formulation development. Its distinctive chemical structure and mechanism of action make it an important compound for research and development involving DNA replication and cellular proliferation.
With the chemical formula C₁₅H₁₈N₄O₅, molecular weight 334.33 g/mol, and CAS Number 50-07-7, Mitomycin C has a well-defined chemical identity suitable for pharmaceutical quality-control and analytical characterization.
Mitomycin C is particularly relevant to oncology pharmaceutical development because of its ability to form covalent DNA cross-links. Following metabolic activation, the molecule generates reactive intermediates that interact with DNA and inhibit DNA replication and transcription.
This mechanism makes Mitomycin C valuable for pharmaceutical products and research programs involving rapidly proliferating cells. It has been incorporated into different pharmaceutical formulations according to the intended therapeutic application and applicable regulatory requirements.
Mitomycin C functions as a bioreductive alkylating agent. Inside cells, enzymatic reduction activates the molecule and generates reactive species capable of modifying DNA.
The activated compound can form DNA-DNA and DNA-protein cross-links, preventing normal DNA replication and transcription. This disruption of essential cellular processes contributes to inhibition of cell proliferation and cytotoxic activity.
Mitomycin C has established applications in specialized pharmaceutical products, particularly within oncology.
Its applications include:
Depending on the formulation and jurisdiction, Mitomycin C is used in specific treatments including certain bladder cancer applications and specialized ophthalmic procedures.
As an established small-molecule pharmaceutical ingredient, Mitomycin C can be characterized using validated analytical methods such as:
Quality assessment should establish the identity, assay, purity and impurity profile of the API in accordance with the applicable approved specification.
Mitomycin C has a distinctive mechanism that differs from many conventional anticancer compounds. Its enzymatic activation and subsequent DNA cross-linking provide a direct mechanism for disrupting DNA replication.
This makes Mitomycin C an important pharmaceutical compound for antineoplastic drug development, oncology formulation research and cancer pharmacology.
Mitomycin C API is relevant to pharmaceutical organizations involved in:
Its established chemical identity and pharmaceutical history make it a useful compound for specialized pharmaceutical development programs.
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |